CN103748229A - 改进的杆状病毒表达系统 - Google Patents

改进的杆状病毒表达系统 Download PDF

Info

Publication number
CN103748229A
CN103748229A CN201280037489.9A CN201280037489A CN103748229A CN 103748229 A CN103748229 A CN 103748229A CN 201280037489 A CN201280037489 A CN 201280037489A CN 103748229 A CN103748229 A CN 103748229A
Authority
CN
China
Prior art keywords
recombinant
baculovirus
gene
genome
baculoviruses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280037489.9A
Other languages
English (en)
Chinese (zh)
Inventor
莱昂内尔·加利贝尔
奥托-维海姆·莫腾
莫尼克·凡奥尔斯
克里斯特尔·里维埃
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genethon
Original Assignee
Genethon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genethon filed Critical Genethon
Publication of CN103748229A publication Critical patent/CN103748229A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14051—Methods of production or purification of viral material
    • C12N2710/14052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201280037489.9A 2011-07-27 2012-07-27 改进的杆状病毒表达系统 Pending CN103748229A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161512142P 2011-07-27 2011-07-27
US61/512,142 2011-07-27
PCT/EP2012/064843 WO2013014294A2 (en) 2011-07-27 2012-07-27 Improved baculovirus expression systems

Publications (1)

Publication Number Publication Date
CN103748229A true CN103748229A (zh) 2014-04-23

Family

ID=46640007

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280037489.9A Pending CN103748229A (zh) 2011-07-27 2012-07-27 改进的杆状病毒表达系统

Country Status (10)

Country Link
US (1) US10480010B2 (enExample)
EP (1) EP2737071B1 (enExample)
JP (1) JP6122430B2 (enExample)
CN (1) CN103748229A (enExample)
BR (1) BR112014001863A2 (enExample)
CA (1) CA2842392C (enExample)
DK (1) DK2737071T3 (enExample)
ES (1) ES2623780T3 (enExample)
IN (1) IN2014CN00688A (enExample)
WO (1) WO2013014294A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114317608A (zh) * 2020-12-28 2022-04-12 陕西杆粒生物科技有限公司 一种基因敲除型杆状病毒表达载体

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
CN112553229A (zh) 2014-11-05 2021-03-26 沃雅戈治疗公司 用于治疗帕金森病的aadc多核苷酸
RU2020108189A (ru) 2014-11-14 2020-03-11 Вояджер Терапьютикс, Инк. Композиции и способы лечения бокового амиотрофического склероза (als)
MX2017006217A (es) 2014-11-14 2018-05-02 Voyager Therapeutics Inc Polinucleotidos moduladores.
EP3230441A4 (en) 2014-12-12 2018-10-03 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
AU2017267665C1 (en) 2016-05-18 2023-10-05 Voyager Therapeutics, Inc. Modulatory polynucleotides
BR112018073472A2 (pt) 2016-05-18 2019-08-27 Voyager Therapeutics, Inc. composições e métodos de tratamento da doença de huntington
WO2018044933A1 (en) 2016-08-30 2018-03-08 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
CA3061652A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
CN111108198A (zh) 2017-05-05 2020-05-05 沃雅戈治疗公司 治疗亨廷顿病的组合物和方法
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CN111132626B (zh) 2017-07-17 2024-01-30 沃雅戈治疗公司 轨迹阵列引导系统
WO2019028306A2 (en) 2017-08-03 2019-02-07 Voyager Therapeutics, Inc. COMPOSITIONS AND METHODS FOR ADMINISTRATION OF ADENO-ASSOCIATED VIRUSES
AU2018338728B2 (en) 2017-09-29 2025-01-02 Centre National De La Recherche Scientifique (Cnrs) Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery
US20200237799A1 (en) 2017-10-16 2020-07-30 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
CN111479924B (zh) 2017-10-16 2024-06-14 沃雅戈治疗公司 肌萎缩性侧索硬化症(als)的治疗
AU2019268330A1 (en) 2018-05-15 2020-11-26 Voyager Therapeutics, Inc. Compositions and methods for the treatment of Parkinson's disease
EP3856762A1 (en) 2018-09-28 2021-08-04 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
WO2020072844A1 (en) * 2018-10-05 2020-04-09 Voyager Therapeutics, Inc. Engineered nucleic acid constructs encoding aav production proteins
CN113166781A (zh) * 2018-10-15 2021-07-23 沃雅戈治疗公司 在杆状病毒/Sf9系统中大规模生产rAAV的表达载体
CN109609552B (zh) * 2018-12-28 2020-04-14 中国科学院武汉物理与数学研究所 重组腺相关病毒的制备方法、系统及重组杆粒
CN113728108A (zh) 2019-02-15 2021-11-30 桑格摩生物治疗股份有限公司 用于生产重组aav的组合物和方法
KR102272651B1 (ko) * 2019-03-28 2021-07-02 충북대학교 산학협력단 외래단백질의 발현량과 발현시간이 증대된 배큘로바이러스
AU2020302861A1 (en) * 2019-06-26 2022-02-24 Virovek, Inc. Baculovirus expression system
WO2022079082A1 (en) 2020-10-15 2022-04-21 F. Hoffmann-La Roche Ag Nucleic acid constructs for simultaneous gene activation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1205741A (zh) * 1995-12-22 1999-01-20 纳幕尔杜邦公司 重组杆状病毒的生产

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
EP0127839B1 (en) 1983-05-27 1992-07-15 THE TEXAS A&M UNIVERSITY SYSTEM Method for producing a recombinant baculovirus expression vector
ZA848495B (en) 1984-01-31 1985-09-25 Idaho Res Found Production of polypeptides in insect cells
FR2664905B1 (fr) * 1990-07-18 1994-08-12 Agronomique Inst Nat Rech Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1205741A (zh) * 1995-12-22 1999-01-20 纳幕尔杜邦公司 重组杆状病毒的生产

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GAILBERT L ET AL: "Baculovirus deleted for chitinase, cathepsin and p10 genes improves purified rAAV8 quality", 《INTERNET CITATION》, 1 January 2010 (2010-01-01), pages 1 *
RICHARD B HITCHMAN ET AL: "Genetic modification of a baculovirus vector for increased expression in insect cells", 《CELL BIOLOGY AND TOXICOLOGY》, vol. 26, no. 1, 5 August 2009 (2009-08-05), pages 57 - 68, XP019767524 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114317608A (zh) * 2020-12-28 2022-04-12 陕西杆粒生物科技有限公司 一种基因敲除型杆状病毒表达载体
CN114317608B (zh) * 2020-12-28 2023-08-22 陕西杆粒生物科技有限公司 一种基因敲除型杆状病毒表达载体

Also Published As

Publication number Publication date
EP2737071B1 (en) 2017-03-15
WO2013014294A3 (en) 2013-04-04
ES2623780T3 (es) 2017-07-12
JP6122430B2 (ja) 2017-04-26
DK2737071T3 (en) 2017-05-08
US20140356904A1 (en) 2014-12-04
EP2737071A2 (en) 2014-06-04
IN2014CN00688A (enExample) 2015-04-03
WO2013014294A2 (en) 2013-01-31
JP2014522658A (ja) 2014-09-08
BR112014001863A2 (pt) 2017-02-21
CA2842392C (en) 2020-09-15
CA2842392A1 (en) 2013-01-31
US10480010B2 (en) 2019-11-19

Similar Documents

Publication Publication Date Title
DK2737071T3 (en) IMPROVED BACULOVIRUS EXPRESSION SYSTEMS
RU2739596C2 (ru) Продуцирование aav в клетках насекомых, способы и композиции для этого
US10767192B2 (en) Baculovirus system for the expression of a gene therapy vector
JP7134240B2 (ja) 組換え型アデノ随伴ウイルスの調製方法、システム及び組換え型バクミド
EP3861107A1 (en) Engineered nucleic acid constructs encoding aav production proteins
JP2025029161A (ja) バキュロウイルス発現系
CN117925723A (zh) 一种杆状病毒-rAAV生产系统中转移载体pAAV-Donor的制备方法及应用
Wu et al. The influence of serial passage on the stability of an exogenous gene expression in recombinant baculovirus
US12416019B2 (en) Expression cassette containing overlapping open reading frames and application
WO2025165781A1 (en) Stable recombinant virus and methods of use thereof
Aurelien et al. Advantages of homologous recombination-over transposition-based systems to generate recombinant baculovirus for AAV vector production
de Jong et al. Productivity and genetic stability of a novel baculovirus vector for multigene expression from independent transgene loci
TW202311528A (zh) 大規模腺相關病毒產生系統

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20140423

RJ01 Rejection of invention patent application after publication